New York, Feb 2, 2026, 16:57 (EST) — After-hours
- Danaher shares closed up about 2.1% at $223.42 and remained steady in after-hours trading
- Just days ahead of this move, the company unveiled its 2026 targets for core revenue growth and adjusted profit.
- Traders are eyeing lab and pharma spending cues while grappling with missing U.S. data due to this week’s shutdown
Danaher’s stock jumped about 2.1% to finish Monday at $223.42, holding its ground in after-hours trading. The shares fluctuated between $216.90 and $224.00 during the session, with around 4.7 million changing hands, ending a four-day losing streak. The broader market also gained, as the S&P 500 climbed 0.54% and the Dow Jones Industrial Average rose 1.05%.
Danaher’s updated forecast is now a bellwether for the life-sciences industry, hinting at whether lab spending is leveling off after recent swings. The company predicts 2026 core revenue—excluding currency and acquisition impacts—will rise between 3% and 6%. Meanwhile, adjusted EPS is expected to come in between $8.35 and $8.50. For Q1, Danaher pointed to low-single-digit core growth.
Chief executive Rainer M. Blair said the company closed the year on a high note, with its portfolio outperforming expectations. He pointed to steadier conditions in China diagnostics, where the business fell by just low single digits in Q4. The firm’s profit outlook for 2026 matched consensus estimates, according to LSEG data.
Life-sciences tools stocks are reacting to hints of increased drugmaker R&D spending, even as universities scale back. On Monday, Revvity posted results showing that improved pharma market conditions and easing policy uncertainty have balanced out weaker academic research budgets. CEO Prahlad Singh noted the company finished 2025 “solidly ahead of our expectations.” Last week, Reuters reported that Thermo Fisher Scientific and Danaher also surpassed fourth-quarter forecasts. Reuters
Danaher’s investor relations page lists an 8-K filed on Jan. 28 alongside its quarterly results, plus an earlier 8-K from Jan. 12. Investors are watching closely for any fresh filings that might shed light on the 2026 outlook.
Still, the rebound doesn’t resolve the key issue: how fast will customers start buying tools and consumables again once inventories run down and budgets free up? If orders in bioprocessing drag, price pressure in China diagnostics worsens, or research budgets face steeper cuts, this year’s targets could face fresh risks.
Macro risks are piling up. The U.S. remains caught in a partial government shutdown, and now the Bureau of Labor Statistics confirmed the January jobs report won’t drop this Friday as scheduled. The House is gearing up to debate the shutdown legislation, with a final vote expected Tuesday. Erica Groshen, ex-BLS commissioner, warned that staff are “already under extreme pressure,” a strain likely to shake up yields and equity multiples. Reuters
Traders will eye whether DHR holds onto Monday’s bounce as new earnings roll in from healthcare and tools companies, alongside continued funding negotiations in Washington. Danaher’s next important date is Feb. 11, when it plans to take down the dial-in replay of its earnings call.
Related articles: NYSE:DHR
